
    the data did not support study endpoints for acute cough, based on an interim efficacy
    analysis; not due to safety concerns.
  
['acute cough']
['gefapixant', 'placebo']

        Inclusion Criteria:

          -  In good general health

          -  Susceptible to human rhinovirus type 16 (HRV-16)

          -  Male or non-pregnant and non-breast feeding female

          -  If female of reproductive potential, agrees to use 1 form of acceptable birth control

        Exclusion Criteria:

          -  Donated blood within 56 days or donated plasma within 7 days prior to dosing

          -  History of significant multiple and/or severe allergies

          -  Recent history of respiratory tract infection

          -  History of cancer

          -  Body mass index <18 kg/m^2 or ≥40 kg/m^2

          -  History of major surgery or loss of 1 unit of blood

          -  History of allergic reaction to sulfonamides

          -  Received medications within 14 days prior to randomization

          -  Significantly abnormal laboratory tests at Screening

          -  Current smoker, smoked within 5 years of Screening, or significant past smoking
             history

          -  History of alcohol or drug abuse
      